Did You Know...
...that the inventor of the electric motor was a blacksmith named Thomas Davenport? Described as "a brilliantly unsuccessful inventor", Davenport invented the first rotary electric motor. In 1836 he headed out -- on foot -- from his Vermont home to file a patent application at the Patent Office in Washington, D.C. By the time he got there, he had squandered away his money and couldn't afford the $30 filing fee so he turned around and went home. When he later mailed in his application with money he'd raised, the Patent office was destroyed in a fire. He did finally get credit for his invention on Feb. 5, 1837.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7507768 | Antidiabetic formulation and method An antidiabetic pharmaceutical formulation is provided, especially adapted for treating Type II diabetes, which includes a combination of metformin and glipizide in a manner to control moisture in the formulation so that the glipizide does not hydrolyze, yet the met... | 03/24/2009 |
| 7507757 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method Compounds are provided which are useful as antidiabetic agents and antiobesity agents and have the structure wherein m is 0, 1 or 2; n is 0, 1 or 2; Q is C or N; A is (CH | 03/24/2009 |
| 7507730 | Substituted pyrazolo[1,5-a]pyrimidines as potassium channel activators Novel heterocyclic dihydropyrimidine compounds useful as inhibitors of potassium channel function (especially inhibitors of the Kv1 subfamily of voltage gated K+ channels, especially inhibitors Kv1.5 which has been linked to the ultr... | 03/24/2009 |
| 7488725 | Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase IV and methods Compounds are provided having the formula: wherein R1, R2, R2′, R3, R3′, R4, R4′, R5, X, Y and Z are as defined herein. ... | 02/10/2009 |
| 7470810 | Alkyl and aryl-thiotrifluoroacetates and process Novel C3-C19 alkyl- and aryl-thiotrifluoroacetates are provided which have the structure wherein Q is C9-C19 alkyl or aryl, and are useful protecting agents for the amino or hydro... | 12/30/2008 |
| 7462616 | Pyrrolo-triazine aniline compounds useful as kinase inhibitors Compounds having the formula (I), and pharmaceutically acceptable salts, prodrugs, and solvates thereof, are useful as kinase inhibitors, wherein R1, R2, R3, R4, R5, R | 12/09/2008 |
| 7459460 | Trisubstituted heteroaromatic compounds as calcium sensing receptor modulators Trisubstituted heteroaromatic compounds having the structure are provided, wherein X is C or N; A and B are each independently CH or N, with the proviso that A and B canno... | 12/02/2008 |
| 7456188 | C-5 substituted quinazolinone derivatives as selective estrogen receptor beta modulators The present application describes compounds according to Formula I, wherein Q, R1, R2 and X are described herein, that are useful as Estrogen Receptor Beta (ERβ) modulators. Additionally, the present application describes pharmaceutical compos... | 11/25/2008 |
| 7452907 | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method Compounds are provided which have the structure wherein Q is C or N, X1 is C or N, and R1, R2, R2a, R2b, R2c, R3, Y, A, m, n, X2, X | 11/18/2008 |
| 7425550 | Lactam glycogen phosphorylase inhibitors and method of use A compound of formula I is provided having the structure wherein W is as defined herein; X is —CHR5O—; Y is a bond; Z is a... | 09/16/2008 |
| 7420059 | HMG-CoA reductase inhibitors and method Compounds are provided having the following structure and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, U, V, W, Y... | 09/02/2008 |
| 7396935 | Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors The present invention relates to compounds having the formula, and pharmaceutically-acceptable salts, prodrugs, solvates, isomers, and/or hydrates thereof, wherein Q is an optionally-substituted pyridyl, ring; R2 | 07/08/2008 |
| 7390810 | Pyrazole-amine compounds useful as kinase inhibitors The present invention provides pyrazole derived compounds of formula (I) useful for treating p38 kinase-associated conditions, where G, X, R1, R2, R3, R4, R5, R6 | 06/24/2008 |
| 7388098 | Dynamic resolution of isomers and resolved isomers Provided is a dynamic resolution method of enriching a desired isomer of an alpha-substituted carboxylic acid relative to an undesired isomer, the method comprising: (a) in a solvent, contacting the alpha-substituted carboxylic acid, wherein the alpha substitution i... | 06/17/2008 |
| 7384958 | Quinoline inhibitors of cGMP phosphodiesterase Compounds of the formula (I) are useful as inhibitors of cGMP PDE especially Type 5. ... | 06/10/2008 |
| 7381730 | 3-arylquinazoline derivatives as selective estrogen receptor beta modulators Novel quinazoline derivatives possessing activity as estrogen receptor beta (ERβ) modulators are provided which have the general formula I wherein X is O or S; A and B ar... | 06/03/2008 |
| 7378430 | Quinoline inhibitors of cGMP phosphodiesterase Compounds of the formula (I) are useful as inhibitors of cGMP PDE especially Type 5. ... | 05/27/2008 |
| 7371759 | HMG-CoA reductase inhibitors and method Compounds are provided having the following structure which are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol, and treat... | 05/13/2008 |
| 7365208 | Method for preparing irbesartan and intermediates thereof A method for preparing irbesartan and intermediates thereof. Irbesartan has the structure of formula I, ... | 04/29/2008 |
| 7338954 | Compounds useful as motilin agonists and method A method is provided for treating disorders of gastrointestinal motility which include the steps of administering to a patient in need of treatment of a compound having the structure or a pharmaceutically acceptable salt th... | 03/04/2008 |
| 7326705 | Heterocyclic sodium/proton exchange inhibitors and method Heterocyclic are provided which are sodium/proton exchange (NHE) inhibitors which have the structure wherein n is 1 to 5; X is N or C—R5 wherein R5 is H, halo, alkenyl, alkynyl, alkoxy, al... | 02/05/2008 |
| 7326706 | Pyrazine modulators of cannabinoid receptors The present application describes compounds according to Formula I, wherein A, G1, G2 and R1 are described herein. Additionally, the present application describes pharmaceutical compositions comprising at least one compound according... | 02/05/2008 |
| 7279485 | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method Substituted heterocyclic derivatives are provided which have the structure wherein Z1 is (CH2)q or C═O; Z2 is (CH2)... | 10/09/2007 |
| 7262195 | Compounds useful as motilin agonists and method Compounds are provided which are useful in treating disorders of gastrointestinal motility and which have the structure or a pharmaceutically acceptable salt thereof, a prodrug ester thereof, and all stereoisomer... | 08/28/2007 |
| 7256208 | Monocyclic -Aryl hydantoin modulators of androgen receptor function The present invention relates to novel compounds useful in the treatment of androgen receptor associated conditions, such as age-related diseases, pharmaceutical compositions containing at least one of the compounds of the present invention and methods of treating a... | 08/14/2007 |
| 7241780 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method Compounds are provided which have the structure wherein Q is C or N, A is O or S, Z is O or a bond, X is CH or N and R1, R2, R2a, R2b, R2c, R3, Y,... | 07/10/2007 |
| 7223573 | Enzymatic ammonolysis process for the preparation of intermediates for DPP IV inhibitors An enzymatic ammonolysis process is provided for the preparation of intermediates used in preparing dipeptidyl peptidase IV inhibitors wherein the enzyme Candida antarctica lipase-B is used to catalyze the ammonolysis process. ... | 05/29/2007 |
| 7214702 | Process for producing a dipeptidyl peptidase IV inhibitor A process is provided for preparing the dipeptidyl peptidase of the structure I (also referred to as saxaglipitin) by direct dehydration, in one pot, of the amide II | 05/08/2007 |
| 7211676 | Method for preparing irbesartan and intermediates thereof A method for preparing irbesartan and intermediates thereof. Irbesartan has the structure of formula I, ... | 05/01/2007 |
| 7205322 | Thiazolidine compounds as calcium sensing receptor modulators The present invention relates to modulators of the calcium sensing receptor having the formula I wherein Ar1, X, J, R1, R2, R3... | 04/17/2007 |
| 7186846 | Process for preparing a dipeptidyl peptidase IV inhibitor and intermediates employed therein A process is provided for preparing a dipeptidyl peptidase IV inhibitor of the structure wherein is treated with TFAA in isopropyl acetate to protect the ter... | 03/06/2007 |
| 7183321 | Antidiabetic formulation and method An antidiabetic pharmaceutical formulation is provided, especially adapted for treating Type II diabetes, which includes a combination of metformin and glipizide in a manner to control moisture in the formulation so that the glipizide does not hydrolyze, yet the met... | 02/27/2007 |
| 7175856 | Palatable oral suspension and method A drug formulation in the form of a dry powder is provided which when mixed with water forms a palatable oral suspension substantially free of bitter taste, the dry powder being formed of a drug, preferably des-quinolone, which in solution has a bitter taste, and a ... | 02/13/2007 |
| 7148348 | Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors A process is provided for the process for preparing a pyrrolotriazine aniline p38 kinase inhibitor such as amide II by the direct aminolysis of the ester I w... | 12/12/2006 |
| 7141694 | Enzymatic resolution of aryl and thio-substituted acids Provided is a method of resolving a racemic mixture of a compound of formula I to obtain a desired enantiomer: wherein Ar is C6 or C10 aromatic group that can be substituted with H, C1 ... | 11/28/2006 |
| 7122207 | High drug load acid labile pharmaceutical composition A high drug load spheronized beadlet is provided wherein said beadlet comprises about 80% to 100% by weight of an acid labile medicament, preferably didanosine, about 0% to about 10% by weight of a disintegrant, and about 0% to about 10% by weight of a binder select... | 10/17/2006 |
| 7115587 | Aripiprazole complex formulation and method An aripiprazole formulation is provided which includes the antipsychotic agent aripiprazole in the form of an inclusion complex in a β-cyclodextrin, preferably, sulfobutyl ether β-cyclodextrin (SBECD), which in the form of an injectable produces reversible general... | 10/03/2006 |
| 7105537 | 2-substituted cyclic amines as calcium sensing receptor modulators The present invention relates to modulators of the calcium sensing receptor having the formula I wherein Ar1, X, n, R1, R2, R3 and Q ... | 09/12/2006 |
| 7098235 | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds Prodrugs of glycogen phosphorylase inhibiting compounds are provided which are useful in treating diabetes, having the formula I G(—O2CR′)m(—OH)n(—O2C(CH2)pCH3)q | 08/29/2006 |
| 7084162 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method Compounds are provided which have the structure wherein Q is C or N, A is O or S, Z is O or a bond, X is CH or N and R1, R2, R2a, R2b, R2c, R3, Y, x, m,... | 08/01/2006 |
